Fosun Pharmaceutical: Subsidiary's drug receives approval for clinical trials.

Fosun Pharma announced that its holding subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., and its holding subsidiary have received approval from the National Medical Products Administration to conduct Phase I clinical trials of HLX97 for the treatment of advanced/metastatic solid tumors.